Mark Nuijten EPA 2021 13 April 2021 Mark Nuijten An innovative pricing model to assess the price of expensive drugs with an orphan indication Lees meer
Innovation Premium for Innovative Orphan Drugs in Oncology and Rare Diseases 3 December 2020 Mark Nuijten Lees meer
Guest lecture for Colombian American Chamber of Commerce on Pricing Policy for Orphan Drugs 25 November 2020 Mark Nuijten Lees meer
Milestone of more than 10’000 views on our policy paper challenging the ICER 12 September 2020 Mark Nuijten Lees meer
Increasing interest in our Pricing Model and Algorithm for "expensive" drugs 1 April 2018 Mark Nuijten Lees meer
Evaluation and valuation of ultra-innovative drugs: a new concept 1 August 2016 Mark Nuijten Lees meer
